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This symposium highlights selected topics in antimicro-
bial resistance: community-acquired methicillin-resistant
Staphylococcus aureus, malaria, reducing inappropriate
antimicrobial drug prescribing for outpatient respiratory
infections, and addressing the human health impact of
antimicrobial drug use in food animals.
Dr. Timothy Naimi discussed community-acquired
methicillin-resistant Staphylococcus aureus (CMRSA) infec-
tions, which have been reported in the Western Pacific and
North America with increasing frequency. Few incidence data
are available, but reports show a disproportionate
distribution among racial minorities and groups with low
socioeconomic status. CMRSA infections resembled commu-
nity-acquired methicillin-susceptible S. aureus infections
more than MRSA infections acquired in health-care facilities.
Patients with CMRSA were young, healthy, and lacked
risk factors for MRSA (recent hospitalization, dialysis, and
injection drug use), and they had predominantly skin and soft
tissue infections; four deaths due to invasive CMRSA
infections were reported in the United States. Unlike
nosocomial MRSA, CMRSA is sensitive to multiple non-beta-
lactam antibiotics. CMRSA isolates have the mec A gene and
distinct pulsed-field-gel electrophoresis patterns. CMRSA
presents a clinical challenge because most community-
acquired S. aureus infections are diagnosed without taking a
culture, and the patient is treated with beta-lactam drugs.
Improved surveillance and efforts to define risk factors are
under way.
Dr. Pascal Ringwald reviewed antimalarial drug
resistance, which greatly hinders malaria control since no
vaccine will be available in the near future. Resistance of
Plasmodium falciparum to chloroquine, the most frequently
used antimalarial drug, is found in nearly all malaria-
endemic countries. Resistance also affects all other
antimalarial drugs; cross-resistance occurs against drugs in
the same group.
In recent years, chloroquine-resistant P. vivax has been
reported in Southeast Asia and in South America. Drug
resistance increases illness and death, especially among
children. As the number of new antimalarial agents is
limited, the use of drug combinations is under evaluation.
WHO supports national malaria control programs to monitor
antimalarial drug resistance in sentinel sites. Decisions to
change drug policy should be based on the results of
monitoring in these sites. The establishment of a new policy
must entail a rational use of drugs and improved compliance.
Dr. Richard Besser discussed efforts to reduce
inappropriate antibiotic prescribing for outpatient respirato-
ry infections in the United States. Over 40% of outpatient
antibiotic prescriptions are for viral illnesses, which are not
affected by antibiotics. CDC’s educational campaign, targeted
to clinicians and patients, involves partnerships with health
departments, health-care delivery organizations, health-care
purchasers, medical societies, and others. Materials and
information are available at www.cdc.gov/drugresistance.
Controlled trials of interventions demonstrated notable
reductions in antibiotic prescriptions written in Denver,
central Wisconsin, and rural Alaska.
Successful interventions were multifaceted and directed
at both clinicians and patients. Clinician interventions
included peer education using opinion leaders, improving
diagnosis of acute otitis media, and feedback on group-
prescribing practice. Patient interventions included educa-
tion in the community (day care centers, health fairs), homes
(reminder refrigerator magnets), and physician offices (videos
in waiting rooms). CDC is expanding this campaign and
seeking to assess its impact in larger areas.
Dr. Sharon Thompson described Food and Drug
Administration (FDA) initiatives to address the human
health impact of antimicrobial drug use in food animals.
These initiatives include regulatory changes, antimicrobial
resistance monitoring, risk assessment, promoting judicious
drug use, and research. FDA has concluded that past
regulations are no longer adequate to preserve important
antimicrobial drugs for human use when their use in food
animals may contribute to antimicrobial resistance. A
proposed framework would classify antimicrobial agents
according to their importance in human medicine and the
likelihood that human exposure to them from consuming food
animals containing them would create more resistant
bacteria. Preapproval studies would assess resistance
development and pathogen load in treated animals. Specified
thresholds of resistance in human and animal isolates would
provide risk management tools—as these thresholds were
approached, drug use in animals could be restricted.
FDA is currently finalizing a risk assessment of
fluoroquinolone-resistant  Campylobacter infection and its
relationship to fluoroquinolone use in poultry and is
beginning an assessment of quinupristin/dalfopristin-
resistant  Enterococcus faecium and its relationship to
virginiamycin use as a growth promotant. Visit the FDA
website at www.fda.gov.
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